Form 8-K REGENERON PHARMACEUTICAL For: Aug 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating
August 5, 2014 12:29 PM EDTRoth Capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) at Buy with a target price of $399 following Q2 results.
Analyst Joseph Pantginis commented, REGN 2Q14 results show a 45% year-to-year growth in revenue as well as a 26% Eylea net sales growth, demonstrating the effective market penetration of the product. Recall that Eylea is already approved in the U.S. and E.U. for wet AMD and macular edema... More
